MedDataX Logo

Effects of Clopidogrel and Clarithromycin on the Oral Disposition of Sibutramine in Healthy Subjects

NCT ID: NCT01421706

Last Updated: 2012-09-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-07-31

Study Completion Date

2009-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Effects of clopidogrel and clarithromycin on the oral disposition of sibutramine in healthy subjects

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1\. Plasma concentrations of sibutramine and its two active metabolites after single oral dose of sibutramine were determined in Korean healthy male subjects with different CYP2B6 genotypes (CYP2B6\*1/\*1, \*1/\*6 and \*6/\*6), either alone or after four-day pretreatment with clopidogrel or clarithromycin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

clarithromycin sibutramine clopidogrel

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sibutramine-clopidogrel

sibutramine-clopidogrel

Group Type ACTIVE_COMPARATOR

Sibutramine-clopidogrel

Intervention Type DRUG

Sibutramine-clopidogrel

sibutramine-clarithromycin

sibutramine-clarithromycin

Group Type ACTIVE_COMPARATOR

sibutramine-Clarithromycin

Intervention Type DRUG

sibutramine-Clarithromycin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sibutramine-clopidogrel

Sibutramine-clopidogrel

Intervention Type DRUG

sibutramine-Clarithromycin

sibutramine-Clarithromycin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* must be healthy volunteer

Exclusion Criteria

* must not be under 18 years old
Minimum Eligible Age

19 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Inje University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jae-Gook Shin

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

JaeGook Shin, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Inje University

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

08-073

Identifier Type: -

Identifier Source: org_study_id